Non-small cell lung cancer (NSCLC) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051128

NSCLC restriction and item codes

Do not share these attachments externally. See Freedom of Information - Information Publication Scheme.

$\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.png$ PBS NSCLC restriction and item codes

Contact details

PBS Complex Drugs Programs

Forms

Non-small cell lung cancer - crizotinib or entrectinib - initial authority application (PB156)

Services Australia website

Non-small cell lung cancer

External websites

PBS schedule for non-small cell lung cancer

FAQs from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item	Description
1	Can patients switch medications? There is no change restriction. To switch between crizotinib and entrectinib, an initial application must be submitted for the required medication. The alternate agent can only be requested due to intolerance, not failure.
2	Does a patient have to requalify if there is a break in treatment? No, providing the patient did not develop disease progression whilst receiving PBS-subsidised treatment. Continuing treatment can be requested irrespective of any breaks in therapy.
3	How to answer the prescriber type question that is not on the form? For written applications received via HPOS or mail, use the prescriber type displayed in OPA to complete the prescriber type question.